What is TB-500?
TB-500 is a synthetic 7 amino acid fragment of thymosin beta-4, a 43 amino acid repair protein found in nearly all human cells. FDA describes TB-500 as an acetylated copy of amino acids 17 to 23 (LKKTETQ) of that protein and states that thymosin beta-4 and TB-500 are not the same substance, even though many websites use the two names interchangeably. No indexed human study of TB-500 itself exists: FDA's July 2026 review found no report of TB-500 being given to humans. Every human trial cited for it used full-length thymosin beta-4, a different substance. In those trials, two intravenous (into a vein) phase 1 safety studies in healthy volunteers found thymosin beta-4 well tolerated, a 73 person phase 2 trial of a topical form for venous leg ulcers reported acceptable safety and a possible healing benefit, and a 72 person eye drop trial for dry eye missed both primary endpoints (its main goals). Those trials do not count toward TB-500's grade. For TB-500 itself the indexed evidence is a horse study and a rat study of how the body breaks it down, plus a cell study in which it did not close scratch wounds, so PeptideAgent grades it animal-only. Sellers often describe TB-500 as thymosin beta-4, and FDA reports that different active ingredients have been sold under the same common name, so whether a given product contains the fragment or the full-length peptide is not verified. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient TB-500 by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add TB-500 to the bulks list, and does not change its evidence grade. It is prohibited by WADA under section S2.
TB-500 is a synthetic N-acetylated 7 amino acid fragment (amino acids 17 to 23, LKKTETQ) of thymosin beta-4, a 43 amino acid actin sequestering protein. It is also known as TB 500, TB500, TB-500 peptide, Thymosin beta-4, fragment (LKKTETQ), Thymosin beta-4 fragment, Ac-LKKTETQ, N-acetylated thymosin beta-4 fragment 17-23.
How does it work?
TB-500 is a synthetic, N-terminally acetylated copy of amino acids 17 to 23 (LKKTETQ) of thymosin beta-4, the 43 amino acid protein that is the main actin sequestering protein in mammalian cells. The fragment contains the actin binding region of thymosin beta-4, and FDA's July 2026 review describes it as hypothesized, not shown, to share the parent protein's actin buffering role. The mechanisms usually quoted for TB-500 were documented with full-length thymosin beta-4 in rodent and cell work: it binds monomeric G-actin, promotes keratinocyte, endothelial, and cardiomyocyte migration, reduces inflammation and myofibroblast driven scarring, and forms a complex with PINCH and integrin linked kinase (ILK) that activates the survival kinase Akt. FDA notes that acetylation changes a peptide's charge and binding properties, so results for the non-acetylated fragment cannot be directly extrapolated to TB-500. In a 2024 cell study, TB-500 itself did not close scratch wounds in cultured fibroblasts, while one of its breakdown products did. None of these mechanisms has been studied in humans receiving TB-500.
| Cluster | Tissue repair and healing |
|---|---|
| Routes | Subcutaneous or intramuscular injection (as sold, and the routes FDA evaluated); Subcutaneous injection in horses and intraperitoneal injection in rats (TB-500 metabolism studies); Intravenous infusion, topical application, and eye drops (human trials of full-length thymosin beta-4, not TB-500) |
| Conditions studied | Tendon injury and tendinopathy; Muscle recovery and injury; Wound healing; Traumatic brain injury; Osteoarthritis |
| Record | v4, reviewed, verified Nov 1, 2026 |
TB-500 benefits: what the evidence shows
No indexed human study of TB-500 itself has been identified, and FDA's July 2026 review found no report of TB-500 being administered to humans. The indexed work on TB-500 is limited to animal and lab studies: a horse study and a rat study that tracked how the peptide is absorbed and broken down, and a 2024 cell study in which TB-500 did not close scratch wounds in cultured fibroblasts while one of its breakdown products did. An older mouse study found that the same 7 amino acid sequence without the acetyl group sped wound repair in aged mice, but FDA says that result cannot be directly extrapolated to TB-500. FDA identified no animal study testing whether TB-500 promotes wound healing and no toxicity studies of it. The human trials often cited for TB-500 all used full-length thymosin beta-4, which FDA says is not the same substance as TB-500. In those trials, two intravenous phase 1 studies in healthy volunteers found thymosin beta-4 well tolerated, a phase 2 trial of a topical form in 73 people with venous ulcers reported acceptable safety and a possible healing benefit, and a phase 2 eye drop trial in 72 people with dry eye missed both primary endpoints though some secondary endpoints improved. The widely quoted rodent wound and heart repair results (for example reepithelialization up 42% at 4 days in rats) are also thymosin beta-4 results. Studies of a different substance are listed in the evidence table but do not raise the grade, so TB-500 stays animal-only.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 4 | 269 |
| Human observational studies | 0 | n/a |
| Animal studies | 6 | n/a |
| All indexed studies | 10 | 269 |
Human evidence
No indexed human study of TB-500 identified. FDA's July 2026 briefing reports that its literature search found no article in which TB-500 was administered to humans and no human pharmacokinetic study by any route. The trials below are thymosin beta-4 trials: they tested the full-length 43 amino acid peptide, which FDA says is not the same substance as TB-500, and they do not count toward TB-500's grade. A randomized, placebo controlled phase 1 study gave intravenous synthetic thymosin beta-4 to 40 healthy adults as a single dose and then daily for 14 days; adverse events were infrequent and mild or moderate, with no dose limiting toxicity or serious adverse events. A randomized, double blind phase 1 study of intravenous recombinant human thymosin beta-4 in healthy volunteers (54 single dose and 30 multiple dose participants) likewise reported mild to moderate adverse events and no serious ones. Both were safety studies for heart attack drug development, not tests of healing. A double blind, placebo controlled phase 2 trial of topical thymosin beta-4 in 73 patients with venous stasis ulcers at eight European sites found safety comparable to placebo and suggested that one of the tested strengths may speed healing. A single center, double masked, placebo controlled phase 2 trial of thymosin beta-4 eye drops in 72 adults with moderate to severe dry eye for 28 days missed both primary endpoints (ocular discomfort and inferior corneal staining), while discomfort in the adverse environment challenge fell 27% relative to placebo and some other secondary endpoints improved. A review of two phase 2 trials of topical thymosin beta-4 in venous stasis and pressure ulcers reported faster healing, by almost a month, in patients who healed. None of these studies tested TB-500.
Animal evidence
Animal and lab work on TB-500 itself is limited. In thoroughbred horses given TB-500 by subcutaneous injection, the peptide and its breakdown products were detected in plasma and urine, in a study designed for doping control. In rats given TB-500, the peptide was broken down into shorter fragments that were measured in urine; in the same 2024 study TB-500 showed no cytotoxicity and did not significantly close scratch wounds in cultured fibroblasts, while its metabolite Ac-LKKTE did. FDA's July 2026 review identified no in vivo animal study testing whether TB-500 promotes wound healing and no animal toxicity studies. A related peptide, the same LKKTETQ sequence without the acetyl group, promoted dermal wound repair in aged mice to a degree comparable to full-length thymosin beta-4; FDA cautions that this cannot be directly extrapolated to TB-500. The widely quoted rodent results belong to full-length thymosin beta-4, not TB-500: in a rat full thickness wound model, thymosin beta-4 given topically or intraperitoneally increased reepithelialization by 42% at day 4 and up to 61% at day 7, increased wound contraction, collagen deposition, and angiogenesis, and stimulated keratinocyte migration 2 to 3 fold in vitro; in mice with coronary artery ligation, thymosin beta-4 upregulated ILK and Akt activity, enhanced early cardiomyocyte survival, and improved cardiac function.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry2012 PMID 23084823 | TB-500 (N-acetylated LKKTETQ): detection and metabolism study in horses given a single dose, plus in vitro metabolite identificationHorses | TB-500 and its metabolites were detected in plasma and urine after administration; a doping control method, not a test of healing or safety | Evidence: Animal-only evidence |
| Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro2024 PMID 38382158 | TB-500 (Ac-LKKTETQ): metabolism in rats, human serum, and in vitro enzyme systems, plus cytotoxicity and scratch wound assays in cultured fibroblastsRats and cultured fibroblasts | TB-500 was broken down into shorter acetylated fragments; no cytotoxicity; TB-500 itself did not significantly close scratch wounds, and only the metabolite Ac-LKKTE did | Evidence: Animal-only evidence |
| Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice2003 PMID 12581423 | Full-length thymosin beta-4 and the non-acetylated LKKTETQ fragment (not TB-500, which is acetylated): dermal wound models in diabetic and aged micedb/db diabetic mice and aged mice | Thymosin beta-4 increased wound contracture and collagen deposition; the non-acetylated 7 amino acid fragment promoted repair in aged mice comparably to the full-length peptide. FDA says this cannot be directly extrapolated to TB-500 | Evidence: Animal-only evidence |
| Thymosin beta4 accelerates wound healing1999 PMID 10469335 | Full-length thymosin beta-4 (not TB-500): rat full thickness wound model plus keratinocyte migration assayRats and cultured keratinocytes | Reepithelialization increased 42% at day 4 and up to 61% at day 7 versus saline; more contraction, collagen, and angiogenesis; keratinocyte migration up 2 to 3 fold. Thymosin beta-4 study, not a TB-500 study | Evidence: Animal-only evidence |
| Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair2004 PMID 15565145 | Full-length thymosin beta-4 (not TB-500): mouse coronary artery ligation model plus embryonic and postnatal cardiomyocyte cultureMice and cultured cardiomyocytes | Thymosin beta-4 formed a complex with PINCH and ILK, activated Akt, enhanced early myocyte survival, and improved cardiac function after infarction. Thymosin beta-4 study, not a TB-500 study | Evidence: Animal-only evidence |
| Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications2012 PMID 22074294 | Narrative review of full-length thymosin beta-4 (not TB-500)Animal models of skin, eye, heart, and brain injury and early clinical programs | Summarizes actin binding, cell migration, anti-inflammatory, and anti-fibrotic mechanisms and the rationale for clinical trials in wounds, cornea, heart, and CNS. Thymosin beta-4 study, not a TB-500 study | Evidence: Animal-only evidence |
| A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers2010 PMID 20536472 | Full-length synthetic thymosin beta-4 given intravenously (not TB-500): randomized, placebo controlled phase 1 ascending dose study, single dose then 14 daily dosesn = 40 Healthy adult volunteers | Adverse events infrequent and mild to moderate; no dose limiting toxicity or serious adverse events; safety study only, healing not tested. Thymosin beta-4 trial: does not count toward TB-500's grade | Evidence: Human RCT evidence |
| A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers2021 PMID 34346165 | Full-length recombinant human thymosin beta-4 given intravenously (not TB-500): randomized, double blind phase 1 study, single and multiple dosesn = 84 Healthy adult volunteers (54 single dose, 30 multiple dose) | Adverse events mild to moderate; no dose limiting toxicity or serious adverse events; no accumulation with daily dosing; safety study only. Thymosin beta-4 trial: does not count toward TB-500's grade | Evidence: Human RCT evidence |
| The effect of thymosin treatment of venous ulcers2010 PMID 20536470 | Full-length synthetic thymosin beta-4 applied topically (not TB-500): double blind, placebo controlled, dose escalation phase 2 trial at eight European sitesn = 73 Patients with venous stasis ulcers | Safety of all tested strengths acceptable and comparable to placebo; efficacy findings suggested one strength may speed healing, mainly in small to moderate or mild to moderate wounds. Thymosin beta-4 trial: does not count toward TB-500's grade | Evidence: Human RCT evidence |
| Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model2015 PMID 26056426 | Full-length thymosin beta-4 eye drops (not TB-500): single center, double masked, placebo controlled phase 2 trial, 28 days of treatmentn = 72 Adults with moderate to severe dry eye | Neither primary endpoint (ocular discomfort, inferior corneal staining) significantly different from placebo; several secondary endpoints improved, including 27% lower discomfort in the adverse environment challenge; no adverse events observed. Thymosin beta-4 trial: does not count toward TB-500's grade | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Tendon injury and tendinopathy | Evidence: Animal-only evidence | The rat wound closure and cell migration results cited here came from full-length thymosin beta-4, not TB-500. TB-500 itself has not been tested for tendon healing in animals or people. |
| Muscle recovery and injury | Evidence: Animal-only evidence | The cell migration and anti-inflammatory effects often cited came from full-length thymosin beta-4 in animal models, not TB-500. TB-500 itself has not been tested for muscle injury in animals or people. |
| Wound healing | Evidence: Animal-only evidence | The cited rat study found faster wound closure with full-length thymosin beta-4, not TB-500. FDA identified no animal study testing whether TB-500 itself promotes wound healing and no report of it being given to humans, and in a 2024 cell study TB-500 did not close scratch wounds in cultured fibroblasts. |
| Traumatic brain injury | Evidence: Animal-only evidence | The rat study that found better functional recovery and brain remodeling after TBI used full-length thymosin beta-4, not TB-500. TB-500 itself has not been tested in brain injury in animals or people. |
| Osteoarthritis | Evidence: Animal-only evidence | The animal tissue repair data cited for it came from full-length thymosin beta-4, not TB-500. TB-500 itself has no joint study in animals or people. |
Is TB-500 legal in the United States?
FDA and compounding status
TB-500 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA's withdrawn list names it Thymosin beta-4, fragment (LKKTETQ). FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026 for wound healing: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds TB-500 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add TB-500 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- HHS
HHS draft policy lets licensed pharmacies compound six peptides without enforcement action
HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- PCAC
FDA advisory committee reviews six peptides; FDA's briefing recommends against listing
At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.
Regulatory: Nomination withdrawnSource: FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slides - FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Full tracker for TB-500 or the category-wide tracker.
Email me when TB-500's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of TB-500 used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. No human study of TB-500 has been published, so no human dose exists for it. The human studies of full-length thymosin beta-4 (intravenous phase 1 studies, a topical form for skin ulcers, and eye drops) tested a different substance, and the horse and rat studies of TB-500 were detection and metabolism studies; none of these translate to a human dose of TB-500.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous or intramuscular injection (as sold, and the routes FDA evaluated) |
| 2 | Subcutaneous injection in horses and intraperitoneal injection in rats (TB-500 metabolism studies) |
| 3 | Intravenous infusion, topical application, and eye drops (human trials of full-length thymosin beta-4, not TB-500) |
TB-500 side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No human safety data for TB-500: FDA found no report of it being given to humans and no animal toxicity studies |
| 2 | FDA concern: compounded TB-500 may pose a risk of immune reactions (immunogenicity) for certain routes because of aggregation and peptide related impurities |
| 3 | Full-length thymosin beta-4 (a different substance), two phase 1 intravenous studies in healthy volunteers: mild to moderate adverse events, no serious adverse events or dose limiting toxicity |
| 4 | Full-length thymosin beta-4 eye drop trial: no adverse events observed over 28 days |
| 5 | Injection site reactions, headache, and lethargy reported anecdotally |
| 6 | Theoretical cancer concern carried over from thymosin beta-4: it drives cell migration and angiogenesis, and higher tumor levels are associated with invasion and metastasis in colorectal cancer studies (not tested for TB-500, and not shown to be caused by taking either peptide) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | No specific drug interactions have been described in animal work |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Active cancer or history of cancer (theoretical cell migration and angiogenesis concern) |
| 2 | Pregnancy and breastfeeding (no data) |
| 3 | Competitive athletes subject to WADA testing (prohibited at all times under S2) |
How do people access TB-500 legally?
Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Access options
Conditional
Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient TB-500 by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.
Not available
Not available as an FDA approved product.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare TB-500
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [23] [24] [25]
In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds TB-500 as a single-ingredient product by subcutaneous or intramuscular injection, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put TB-500 on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix TB-500 with other peptides are not covered, and state rules still apply. [21] [22]
What FDA found
- July 2026: FDA's review found websites selling TB-500 labeled research use only. It found two websites that said they got TB-500 from a compounding pharmacy, but no pharmacy marketing compounded TB-500. [13]
- July 2026: FDA's BPC-157 review describes a patient who developed significant adverse reactions after using a BPC-157 and TB-500 injection labeled "for research purposes only". [26]
- June 2023: FDA found an online seller taking orders for TB-500 as an injectable and a nasal spray, and called it an unapproved new drug even though the labels disclaimed human use. [27]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [14] [23] [28] [29] [30] [31]
What that means for you
- A pharmacy that compounds TB-500 relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [22]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [31]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [32]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [33] [34]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [14]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, TB-500 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [31]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [35] [36] [37]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [25] [37] [38]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [31] [39] [40] [41] [42] [43]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [31]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [35]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [25]
- Pharmacy: Is this made for me on a prescription written in my name? [38]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [25] [37]
- Prescriber: What is the legal basis for a pharmacy to compound TB-500? Is it FDA approved or on the 503A bulks list? [5] [31]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [25]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [32]
Blends that contain TB-500
TB-500 is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.
- GLOW: with GHK-Cu, BPC-157. No federal basis to compound.
- KLOW: with GHK-Cu, BPC-157, KPV. No federal basis to compound.
- Wolverine stack: with BPC-157. No federal basis to compound.
Frequently asked questions
What is TB-500?
TB-500 is a synthetic peptide made of 7 amino acids. FDA describes it as an acetylated copy of amino acids 17 to 23 (LKKTETQ) of thymosin beta-4, a 43 amino acid repair protein found in nearly all human cells. It is promoted for tendon, muscle, and wound healing, but no human study of TB-500 itself has been published. It is not an FDA approved drug, it is named on the WADA Prohibited List (the World Anti-Doping Agency's banned list), and PeptideAgent grades it animal-only. [7] [11] [13]
TB-500 benefits: what does the evidence show?
No benefit of TB-500 has been shown in humans, because no human study of TB-500 itself has been published, and FDA's July 2026 review found no animal study testing whether it heals wounds. In a 2024 cell study TB-500 did not close scratch wounds in cultured cells, though one of its breakdown products did. The results usually quoted for TB-500 come from full-length thymosin beta-4, which FDA says is not the same substance: faster wound closure in rats (42% more reepithelialization at day 4), better heart function after injury in mice, and small human trials in which a 72 person dry eye trial missed its primary endpoints and a 73 person venous ulcer trial suggested a possible healing benefit. None of that counts as evidence for TB-500, so the benefits people seek it for are unproven. [1] [2] [3] [13] [15] [17]
What are the side effects of TB-500?
There is no human safety data for TB-500. FDA found no report of it being given to humans and no animal toxicity studies, and it flagged a possible risk of immune reactions to compounded TB-500 because of clumping and peptide impurities. The studies often cited for safety tested full-length thymosin beta-4, a different substance: two phase 1 intravenous studies in healthy volunteers reported mild to moderate adverse events and no serious ones, and a 28 day eye drop trial reported no adverse events. Anecdotal reports mention injection site irritation, headache, and lethargy. Unverified research chemical products add contamination and identity risks. [3] [8] [9] [11] [13] [14]
Does TB-500 cause cancer?
No study shows that taking TB-500 causes cancer, but the question has not been tested: FDA found no carcinogenicity study of TB-500. The concern is carried over from the tumor biology of thymosin beta-4, the protein TB-500 is a fragment of. Thymosin beta-4 drives cell migration and blood vessel growth, and in colorectal cancer research higher thymosin beta-4 made cancer cells more invasive and was found at higher levels in liver metastases. That is an association in tumors involving the full-length protein, not proof that taking TB-500 or thymosin beta-4 causes harm, and the phase 1 studies of thymosin beta-4 were too short to detect a cancer signal. People with active or past cancer are the group the concern applies to most. [4] [8] [10] [13]
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a natural 43 amino acid protein. TB-500 is a synthetic 7 amino acid fragment of it: amino acids 17 to 23 (LKKTETQ) with an added acetyl group. FDA's July 2026 review states that thymosin beta-4 and TB-500 are not the same substance, even though many websites use the names interchangeably. Every human trial was done with full-length thymosin beta-4, so those results do not apply to TB-500. One lab analysis of a product sold as TB-500 found the fragment, but FDA reports that different active ingredients have been sold under the same common name, so it is not verified whether a given product sold as TB-500 contains the fragment or the full-length peptide. [11] [13] [19]
Are there TB-500 capsules or nasal sprays?
Oral and nasal TB-500 products are marketed, but FDA found no human study of TB-500 by any route. The human studies of full-length thymosin beta-4, a different substance, used intravenous infusion, eye drops, and a topical form on skin ulcers, and the animal studies of TB-500 gave it by injection. There is no evidence that a capsule or spray delivers the peptide to injured muscle, tendon, or skin. [3] [8] [13] [15] [16] [17]
Is TB-500 FDA approved?
No. TB-500 is not FDA approved for any use. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient TB-500 by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. That is not an FDA approval or a bulks listing, it is not binding, and HHS may revisit it. Products sold as research chemicals for human use are still unapproved drugs. [5] [6] [20] [21] [22]
Is TB-500 banned by WADA?
Yes. The WADA Prohibited List names thymosin beta-4 and its derivatives, including TB-500, under section S2 (peptide hormones, growth factors, related substances and mimetics), prohibited at all times. Athletes subject to testing should not use it. [7]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- TB-500 side effects and benefits: what the evidence shows
No human study of TB-500 has been published, so its side effects in people are unknown. What FDA's 2026 review found, which studies tested a different peptide, and its legal status.
- TB-500 vs thymosin beta-4: is it the same peptide?
FDA says TB-500 and thymosin beta-4 are not the same substance. What each one is, which one the human and animal studies used, capsules and sprays, and the cancer question.
- RFK Jr.'s peptide policy: what HHS changed for BPC-157 and five other peptides
HHS released a draft policy on October 28, 2026: it will not act against licensed compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax under strict conditions. It is not FDA approval.
- GLOW peptide before and after: what the evidence shows
No study has measured GLOW peptide before and after results. What each ingredient's human evidence shows for skin and hair, documented side effects, and the blend's legal status.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- Peptide before and after: trial results vs marketing photos
Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims.
More on the blog
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
- [2]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
- [3]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol 2015PubMed 26056426, 2015
- [4]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [7]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimetics (names thymosin beta-4 and TB-500)WADA, 2026
- [8]Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010PubMed 20536472, 2010
- [9]Wang X et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med 2021PubMed 34346165, 2021
- [10]Wang WS et al. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 2004PubMed 15235586, 2004
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, November 1). TB-500: evidence, legality, and access. https://peptideagent.ai/peptides/tb-500- HTML link
<a href="https://peptideagent.ai/peptides/tb-500">TB-500: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.